VG
☆    

India,
2014-01-13 13:18
(4549 d 22:20 ago)

Posting: # 12160
Views: 1,913
 

 reference replicate design [Design Issues]

Post reply
Dear all

Please let me know if reference replicate design (partial and fully replicate) is acceptable to the KFDA (Korea) for highly variable drugs. If so which methodology is to be followed (USFDA or EMA).


Regards

VG
 
UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
266 visitors (0 registered, 266 guests [including 19 identified bots]).
Forum time: 12:39 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5